Borderline Personality Disorder Clinical Trial
Official title:
Reactivity of Patients With Borderline Personality Disorder to an Ecological Interpersonal Stress : Pathophysiology of Suicidal Behaviors Study Model
Use lay language. According to the World Health Organization 1 death by suicide occurs every 40 seconds, leading suicide prevention to one of the public health priority. BPD (Borderline Personality Disorder) is a common condition affecting 6% of the population. This disorder is characterized by unstable emotions, unstable mood, difficulties with relationship and feer of abandonment. Borderline Personality Disorder is also the psychopathology the most related to suicidal attempts. Indeed, up to 50% of the patients admitted to hospital after a suicide attempt are diagnosis with a Borderline Personality Disorder Negative interpersonal events (events occurring between two people) are known as the main stressor that trigger a suicidal attempt. People with a Borderline Personality Disorder are highly sensitive to it. Moreover, neuropeptides such as oxytocin (OXT), vasopressin and opioid are known to be involved in the regulation of the emotions, especially those linked to relationship. The purpose of this study is to improve knowledge in suicidal behaviors. After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD will be compared to healthy controls (HC). Clinical data reflecting how the participant is feeling will be collected as well.
A dysregulation of the neuropeptides (OXT, vasopressin and opioid) could explain the dysregulation of the emotions of people with Borderline Personality Disorder. Up to this date there is no other study measuring neuropeptides kinetics of patient with Borderline Personality Disorder after an interpersonal stress. This task of stress is meant to reproduce what people with Borderline Personality Disorder suffer in their everyday life (ecological). To reach this point, an imaginary interpersonal stress will be asked to be reproduced by the participants. Neuropeptides concentrations and clinical data (fear, shame, anger, moral pain, compelling needs (suicidal and non-suicidal)) will be collected at different times (pre stress, post stress immediat, 5 minutes post stress,15 minutes post stress and 40 minutes post stress) As copeptin ( fragment C terminal of the vasopressin) and vasopressin are found in stoichiometric concentration in the plasma as copeptin is more stable than vasopressin, plasma copeptin level will be used to reflect the one of vasopressin. The hypothesis is that both the neuropeptide variation and clinical data before and after the interpersonal stress will be higher for the patient with Borderline Personality Disorder than healthy controls. A correlation between clinical assessments and neuropeptides kinetics is expected. This study will help to identify inter-individual and contextual factors impacting neuropeptide's kinetics ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04856449 -
DBT Skills Plus EMDR for BPD and Trauma
|
N/A | |
Active, not recruiting |
NCT04587518 -
Five Factor Model Treatment for Borderline Personality Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Completed |
NCT03677037 -
The Short-Term MBT Project
|
Phase 3 | |
Not yet recruiting |
NCT05989529 -
Delving Into Borderline Personality Disorder Clinical Trial Experiences
|
||
Completed |
NCT02518906 -
Evaluation of AIT Study
|
N/A | |
Completed |
NCT02068326 -
MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Completed |
NCT02108990 -
Acetaminophen and Social Processes
|
Phase 2 | |
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Completed |
NCT01635556 -
Evaluation of a Modified Dialectical Behavior Therapy Program
|
N/A | |
Completed |
NCT02988037 -
Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study
|
N/A | |
Not yet recruiting |
NCT01683136 -
Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder
|
N/A | |
Completed |
NCT02397031 -
Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder
|
N/A | |
Terminated |
NCT01103180 -
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
|
Phase 2 | |
Terminated |
NCT01212588 -
Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
|
Phase 2 | |
Terminated |
NCT00539188 -
N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD
|
Phase 2 | |
Recruiting |
NCT05398627 -
Neurofeedback for Borderline Personality Disorder
|
N/A | |
Recruiting |
NCT03994510 -
SHame prOpensity in bOrderline Personality Disorder
|
N/A | |
Recruiting |
NCT06005129 -
Personality Change Study for Borderline Personality Disorder
|
N/A |